|
1
|
Debes JD and Tindall DJ: Mechanisms of
androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schröder FH: Progress in understanding
androgen-independent prostate cancer (AIPC): A review of potential
endocrine-mediated mechanisms. Eur Urol. 53:1129–1137. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee JD, Ulevitch RJ and Han J: Primary
structure of BMK1: A new mammalian map kinase. Biochem Biophys Res
Commun. 213:715–724. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weldon CB, Scandurro AB, Rolfe KW, Clayton
JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA and Jaffe
BM: Identification of mitogen-activated protein kinase kinase as a
chemoresistant pathway in MCF-7 cells by using gene expression
microarray. Surgery. 132:293–301. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esparis-Ogando A, Díaz-Rodriguez E,
Montero JC, Yuste L, Crespo P and Pandiella A: Erk5 participates in
neuregulin signal transduction and is constitutively active in
breast cancer cells overexpressing ErbB2. Mol Cell Biol.
22:270–285. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mehta PB, Jenkins BL, McCarthy L, Thilak
L, Robson CN, Neal DE and Leung HY: MEK5 overexpression is
associated with metastatic prostate cancer and stimulates
proliferation, MMP-9 expression and invasion. Oncogene.
22:1381–1389. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayashi M and Lee JD: Role of the
BMK1/ERK5 signaling pathway: Lessons from knockout mice. J Mol Med
(Berl). 82:800–808. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kato Y, Tapping RI, Huang S, Watson MH,
Ulevitch RJ and Lee JD: Bmk1/Erk5 is required for cell
proliferation induced by epidermal growth factor. Nature.
395:713–716. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hayashi M, Tapping RI, Chao TH, Lo JF,
King CC, Yang Y and Lee JD: BMK1 mediates growth factor-induced
cell proliferation through direct cellular activation of serum and
glucocorticoid-inducible kinase. J Biol Chem. 276:8631–8634. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cameron SJ, Abe J, Malik S, Che W and Yang
J: Differential role of MEK5alpha and MEK5beta in BMK1/ERK5
activation. J Biol Chem. 279:1506–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
John PC, Mews M and Moore R: Cyclin/Cdk
complexes: Their involvement in cell cycle progression and mitotic
division. Protoplasma. 216:119–142. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang Q, Deng X, Lu B, Cameron M, Fearns C,
Patricelli MP, Yates JR III, Gray NS and Lee JD: Pharmacological
inhibition of BMK1 suppresses tumor growth through promyelocytic
leukemia protein. Cancer Cell. 18:258–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hayashi M, Fearns C, Eliceiri B, Yang Y
and Lee JD: Big mitogen-activated protein kinase 1/extracellular
signal-regulated kinase 5 signaling pathway is essential for
tumor-associated angiogenesis. Cancer Res. 65:7699–7706.
2005.PubMed/NCBI
|
|
18
|
Pi X, Garin G, Xie L, Zheng Q, Wei H, Abe
J, Yan C and Berk BC: BMK1/ERK5 is a novel regulator of
angiogenesis by destabilizing hypoxia inducible factor 1alpha. Circ
Res. 96:1145–1151. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sawhney RS, Liu W and Brattain MG: A novel
role of ERK5 in integrin-mediated cell adhesion and motility in
cancer cells via Fak signaling. J Cell Physiol. 219:152–161. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sticht C, Freier K, Knöpfle K,
Flechtenmacher C, Pungs S, Hofele C, Hahn M, Joos S and Lichter P:
Activation of MAP kinase signaling through ERK5 but not ERK1
expression is associated with lymph node metastases in oral
squamous cell carcinoma (OSCC). Neoplasia. 10:462–470. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou C, Nitschke AM, Xiong W, Zhang Q,
Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L and Yu D: Proteomic
analysis of tumor necrosis factor-alpha resistant human breast
cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal
transition phenotype. Breast Cancer Res. 10:R1052008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chatterjee A, Chatterjee U and Ghosh MK:
Activation of protein kinase CK2 attenuates FOXO3a functioning in a
PML-dependent manner: Implications in human prostate cancer. Cell
Death Dis. 4:e5432013. View Article : Google Scholar : PubMed/NCBI
|
